Brokerages Set OraSure Technologies, Inc. (OSUR) PT at $24.00

Shares of OraSure Technologies, Inc. (NASDAQ:OSUR) have earned an average recommendation of “Hold” from the seven brokerages that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $24.00.

Several brokerages recently commented on OSUR. BidaskClub cut OraSure Technologies from a “sell” rating to a “strong sell” rating in a research note on Thursday, September 20th. TheStreet raised OraSure Technologies from a “c+” rating to a “b” rating in a research note on Thursday, August 9th. Zacks Investment Research cut OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Tuesday, August 7th. Stephens cut OraSure Technologies from an “overweight” rating to an “equal weight” rating in a research note on Monday, July 16th. Finally, ValuEngine raised OraSure Technologies from a “hold” rating to a “buy” rating in a research note on Friday, July 6th.

Shares of NASDAQ OSUR opened at $14.24 on Wednesday. The company has a market capitalization of $945.13 million, a P/E ratio of 27.86, a PEG ratio of 3.43 and a beta of 1.53. OraSure Technologies has a 52 week low of $12.86 and a 52 week high of $22.22.

OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings results on Wednesday, August 8th. The medical instruments supplier reported $0.07 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.04 by $0.03. The business had revenue of $43.60 million during the quarter, compared to analysts’ expectations of $42.24 million. OraSure Technologies had a return on equity of 5.85% and a net margin of 8.38%. The firm’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.09 EPS. On average, research analysts expect that OraSure Technologies will post 0.36 earnings per share for the current year.

In related news, Director Charles W. Patrick sold 8,000 shares of the business’s stock in a transaction that occurred on Monday, August 27th. The stock was sold at an average price of $16.29, for a total value of $130,320.00. Following the completion of the sale, the director now owns 54,298 shares of the company’s stock, valued at approximately $884,514.42. The sale was disclosed in a document filed with the SEC, which is available at this link. Insiders own 2.90% of the company’s stock.

A number of institutional investors have recently made changes to their positions in OSUR. SG Americas Securities LLC bought a new stake in OraSure Technologies during the first quarter worth approximately $113,000. Point72 Asset Management L.P. bought a new stake in OraSure Technologies during the second quarter worth approximately $122,000. Cubist Systematic Strategies LLC bought a new stake in OraSure Technologies during the first quarter worth approximately $139,000. Engineers Gate Manager LP bought a new stake in OraSure Technologies during the second quarter worth approximately $197,000. Finally, Xact Kapitalforvaltning AB bought a new stake in OraSure Technologies during the second quarter worth approximately $198,000. 91.76% of the stock is owned by hedge funds and other institutional investors.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.

Read More: What is a stock buyback?

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply